自体外周血CD34+造血干细胞移植治疗晚期肝硬化的远期疗效

Long-term outcome of autologous peripheral blood CD34+ hematopoietic stem cell transplantation in the treatment of advanced liver cirrhosis

  • 摘要: 目的:探讨自体外周血CD34+造血干细胞移植治疗晚期肝硬化的远期临床疗效。
    方法:采用回顾性横断面研究方法。收集2010年7月至2015年7月四川省人民医院收治的42例晚期肝硬化患者的临床病理资料。患者行自体外周血CD34+造血干细胞移植治疗:每日皮下注射集落刺激因子 5 μg/kg,治疗3~5 d,采集外周血干细胞,采集的干细胞行流式细胞检测CD34+造血干细胞数量达(1.8±1.7)×106/kg。采集后第2天在DSA检查下行经股动脉超选肝动脉植入术或手术经胃网膜右静脉置管至门静脉主干注入,术中监测门静脉压力。术后积极降低门静脉压力,保护肝肾功能;第3天给予抗凝治疗,防止门静脉系统血栓形成。观察指标:(1)治疗情况:CD34+造血干细胞移植后患者基本情况、术后并发症。(2)随访情况:患者生存率、肝功能Child评分、终末期肝病模型(MELD)评分、肝脏活组织病理学检查结果、组织学Knodell评分、慢性肝病健康相关生存质量(HRQL)评分。采用门诊、电话及邮件方式随访,随访内容为检查患者肝肾功能、凝血功能;B超及CT检查患者腹腔积液情况;行肝功能Child及MELD评分;行B超引导下肝脏穿刺取活组织检查;调查患者慢性肝病生存质量。随访时间截至2015年7月。正态分布的计量资料以±s表示,组间比较采用配对设计t检验。偏态分布的计量资料以M(范围)表示。采用KaplanMeier法绘制生存曲线。
    结果:(1)治疗情况:42例患者经自体外周血CD34+造血干细胞移植治疗后,患者精神、睡眠、食欲、大小便情况及症状均有不同程度改善。10例患者发生术后并发症,其中上消化道大出血3例,Ⅰ度肝性脑病3例,术后1个月及3个月各发生肝肾综合征1例均死亡,术后6个月发生门静脉血栓1例,自发性腹膜炎1例,其余患者经对症支持治疗后治愈或好转。(2)随访情况:42例患者获得随访,随访中位时间为 57个月(1~60个月),5年生存率为95.23%。患者术后5年肝功能Child评分及MELD评分分别为(7.1±1.1)分和(14±4)分,与术前的(9.4±1.8)分和(19±5)分比较,差异均有统计学意义(t=1.672, 3.773,P<0.05)。患者肝脏活组织病理学检查结果:移植前患者肝小叶结构紊乱,被纤维切割,肝细胞水肿变性,呈毛玻璃样变,有点状及碎屑坏死;可见汇管区汇管区桥接坏死,汇管区内有纤维组织增生,其内有中等量淋巴细胞、单核细胞浸润,假小叶形成。移植后5年患者正常肝小叶形成明显增多,且分布更加趋近正常,肝细胞水肿变性,见少量点状坏死,未见明显碎屑坏死;汇管区内纤维组织增生较前明显好转,纤维组织明显减少,染色明显变淡。移植后5年患者Knodell评分为(9.9± 2.7)分,与移植前的(14.1±4.1)分比较,差异有统计学意义(t=4.142,P<0.05);HRQL评分为(167±21)分,与移植前的(134±15)分比较,差异有统计学意义(t=3.142,P<0.05)。
    结论:自体外周血CD34+造血干细胞移植能长期有效地改善晚期肝硬化患者的肝功能、肝组织形态学以及提高患者的生命质量。

     

    Abstract: Objective:To investigate the longterm outcome of autologous peripheral blood CD34+ hematopoietic stem cell transplantation in the treatment of advanced liver cirrhosis.
    Methods:The retrospective crosssectional study was adopted. The clinical data of 42 patients with advanced liver cirrhosis who were admitted to the Sichuan Provincial People′s Hospital between July 2010 and July 2015 were collected. The patients underwent autologous peripheral blood CD34+ hematopoietic stem cell transplantation. The 5 μg/kg colonystimulating factors were injected subcutaneously daily for 3-5 days. The peripheral blood stem cells were collected and detected by flow cytometry, showing (1.8±1.7)×106/kg of CD34+ cell. Transfemoral superselective hepatic arterial implantation or catheterization via right gastroepiploic venous to main portal vein (PV) was performed by digital subtraction angiography (DSA) at 2 days after collection, and intraoperative portal venous pressure (PVP) was monitored. PVP was reduced after operation and liver and renal functions were protected. The patients underwent anticoagulation therapy at 3 days for preventing PV thrombosis. Observation indicators included (1) treatment: the basic conditions of patients after CD34+ hematopoietic stem cell transplantation and postoperative complications, (2) followup: survival rate of patients, Child score, model for endstage liver disease (MELD) score, result of biopsy, Knodell score and health related quality of life (HRQL) score. The followup using outpatient examination, telephone interview and Email was performed to detect the liver and renal functions and coagulation function up to July 2015. Peritoneal effusion of patients was detected by B ultrasound and computed tomography (CT) examination. The patients received liver function ChildPugh score, MELD score, percutaneous transhepatic biopsy guided by B ultrasound and HRQL score. Measurement data with normal distribution were presented as ±s, comparison between groups was analyzed by the matched t test. The survival curve was drawn by the KaplanMeier method. Measurement data with skewed distribution were presented as M (range).
    Results:(1) Treatment: the symptoms of spirit, sleep, appetite, urination and defecation in 42 patients were improved after autologous peripheral blood CD34+ hematopoietic stem cell transplantation. Ten patients had postoperative complications, including 3 with upper gastrointestinal hemorrhage, 3 with grade I of hepatic encephalopathy, 2 dying of hepatorenal syndrome at postoperative month 1 and 3, 1 with PV thrombosis at postoperative month 6 and 1 with spontaneous peritonitis. Other patients were cured or improved by symptomatic treatment. (2) Followup situations: 42 patients were followed up for a median time of 57 months (range, 1- 60 months), with 5year survival rate of 95.23%. The Child score and MELD score were 7.1±1.1 and 14±4 at postoperative year 5, 9.4±1.8 and 19±5 before operation, respectively, with statistically significant differences (t=1.672, 3.773, P<0.05). The result of liver biopsy showed that disordered hepatic lobule structures were cut by fibers and groundglass hepatic cells showed symptoms of edema and degeneration with spotty and piecemeal necrosis. Necrosis from portal regions to bridge connection were found, proliferation of fibrous tissue, invasion of moderate amount of lymphocytes and monocytes inside portal regions were also detected, and pseudolobule was formed. At postoperative year 5, hepatic lobule was increased obviously and the distribution tended to normal. Hepatic cells showed symptoms of edema and degeneration with small amounts of spotty necrosis and without piecemeal necrosis. Proliferation of fibrous tissue inside portal regions was improved markedly, fibrous tissues were obviously reduced and stain was significantly fade. Knodell score at postoperative year 5 and before operation was 9.9±2.7 and 14.1±4.1, showing a statistically significant difference (t=4.142, P<0.05). HRQL score at postoperative year 5 and before operation was 167±21 and 134±15, with a statistically significant difference (t=3.142, P<0.05).
    Conclusion:Autologous peripheral blood CD34+ hematopoietic stem cell transplantation can effectively improve liver function and pathological histology of hepatic cirrhosis as well as quality of life in patients with advanced liver cirrhosis.

     

/

返回文章
返回